Gypenosides ameliorate polycystic ovary syndrome via gut microbiota modulation: An integrated gut microbiome and ovarian transcriptome study
Abstract
Polycystic ovary syndrome (PCOS) is a prevalent endocrine disorder with complex metabolic and reproductive manifestations. Gut microbiota dysbiosis has emerged as a key factor in PCOS, yet the causal role of microbiota-targeted interventions remains to be fully defined. In a letrozole-induced rat model, we show that gypenosides (GPs)-bioactive saponins from Gynostemma pentaphyllum-alleviate weight gain, hormonal imbalance, and estrous cycle disruption, alongside reducing systemic oxidative stress and inflammation. Integrated ovarian transcriptomics and gut microbiome 16S rRNA sequencing reveal that GPs modulate ovarian gene expression related to inflammation and cellular function while reshaping gut microbiota by enriching beneficial genera including Lactobacillus and Romboutsia. Fecal microbiota transplantation (FMT) establishes causality: PCOS-derived microbiota transfers disease traits to normal recipients, whereas GPs-conditioned microbiota alleviates PCOS phenotypes in recipients. These findings demonstrate that GPs act through a "gut microbiota-oxidative stress-ovary" axis, supporting GPs as a promising microbiota-targeted intervention for PCOS management.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.